Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyadic International Inc. stock logo
DYAI
Dyadic International
$0.76
-1.3%
$0.82
$0.65
$1.35
$28.06M1.1850,896 shs17,122 shs
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$3.10
$4.66
$0.30
$1.47
$105.77M2.6993,510 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyadic International Inc. stock logo
DYAI
Dyadic International
-1.30%+0.32%-12.14%-10.52%-32.73%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyadic International Inc. stock logo
DYAI
Dyadic International
$0.76
-1.3%
$0.82
$0.65
$1.35
$28.06M1.1850,896 shs17,122 shs
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$3.10
$4.66
$0.30
$1.47
$105.77M2.6993,510 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyadic International Inc. stock logo
DYAI
Dyadic International
-1.30%+0.32%-12.14%-10.52%-32.73%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dyadic International Inc. stock logo
DYAI
Dyadic International
2.33
Hold$3.00294.68% Upside
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest DYAI and ERYP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2026
Dyadic International Inc. stock logo
DYAI
Dyadic International
Reiterated RatingSell (E+)
(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dyadic International Inc. stock logo
DYAI
Dyadic International
$3.09M8.96N/AN/A$0.03 per share25.34
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$32.66M3.24N/AN/A$0.80 per share3.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$7.36M-$0.25N/AN/AN/A-239.67%-695.96%-78.24%5/13/2026 (Estimated)
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
-$240KN/AN/AN/AN/AN/AN/AN/AN/A

Latest DYAI and ERYP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$0.04N/AN/AN/A$0.90 millionN/A
3/25/2026Q4 2025
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$0.03-$0.06-$0.03-$0.06$1.34 million$0.57 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dyadic International Inc. stock logo
DYAI
Dyadic International
N/AN/AN/AN/AN/A
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dyadic International Inc. stock logo
DYAI
Dyadic International
4.08
2.68
2.68
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.32
3.65
3.65

Institutional Ownership

CompanyInstitutional Ownership
Dyadic International Inc. stock logo
DYAI
Dyadic International
27.95%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
1.09%

Insider Ownership

CompanyInsider Ownership
Dyadic International Inc. stock logo
DYAI
Dyadic International
29.50%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
1.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dyadic International Inc. stock logo
DYAI
Dyadic International
736.44 million25.69 millionOptionable
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
4934.12 million33.46 millionNot Optionable

Recent News About These Companies

Royalty Pharma PLC Class A RPRX
Update on Erytech merger with Pherecydes Pharma
ERYTECH Responds to Akkadian’s Disinformation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dyadic International stock logo

Dyadic International NASDAQ:DYAI

$0.76 -0.01 (-1.30%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$0.75 -0.01 (-0.80%)
As of 05/6/2026 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

ERYTECH Pharma stock logo

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.